127 related articles for article (PubMed ID: 31284880)
1. Using Magnetic Resonance Perfusion to Stratify Overall Survival in Treated High-Grade Gliomas.
Fong C; Parpia S; Yemen B; Tsai S; Greenspoon J
Can J Neurol Sci; 2019 Sep; 46(5):533-539. PubMed ID: 31284880
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal DSC-MRI for Distinguishing Tumor Recurrence From Pseudoprogression in Patients With a High-grade Glioma.
Boxerman JL; Ellingson BM; Jeyapalan S; Elinzano H; Harris RJ; Rogg JM; Pope WB; Safran H
Am J Clin Oncol; 2017 Jun; 40(3):228-234. PubMed ID: 25436828
[TBL] [Abstract][Full Text] [Related]
3. Comparison of three different MR perfusion techniques and MR spectroscopy for multiparametric assessment in distinguishing recurrent high-grade gliomas from stable disease.
Seeger A; Braun C; Skardelly M; Paulsen F; Schittenhelm J; Ernemann U; Bisdas S
Acad Radiol; 2013 Dec; 20(12):1557-65. PubMed ID: 24200483
[TBL] [Abstract][Full Text] [Related]
4. Differentiating between Central Nervous System Lymphoma and High-grade Glioma Using Dynamic Susceptibility Contrast and Dynamic Contrast-enhanced MR Imaging with Histogram Analysis.
Murayama K; Nishiyama Y; Hirose Y; Abe M; Ohyu S; Ninomiya A; Fukuba T; Katada K; Toyama H
Magn Reson Med Sci; 2018 Jan; 17(1):42-49. PubMed ID: 28515410
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Diffusion Tensor Imaging and Magnetic Resonance Perfusion Imaging in Differentiating Recurrent Brain Neoplasm From Radiation Necrosis.
Masch WR; Wang PI; Chenevert TL; Junck L; Tsien C; Heth JA; Sundgren PC
Acad Radiol; 2016 May; 23(5):569-76. PubMed ID: 26916251
[TBL] [Abstract][Full Text] [Related]
6. Combined use of susceptibility weighted magnetic resonance imaging sequences and dynamic susceptibility contrast perfusion weighted imaging to improve the accuracy of the differential diagnosis of recurrence and radionecrosis in high-grade glioma patients.
Kim TH; Yun TJ; Park CK; Kim TM; Kim JH; Sohn CH; Won JK; Park SH; Kim IH; Choi SH
Oncotarget; 2017 Mar; 8(12):20340-20353. PubMed ID: 27823971
[TBL] [Abstract][Full Text] [Related]
7. Dynamic contrast-enhanced and dynamic susceptibility contrast perfusion MR imaging for glioma grading: Preliminary comparison of vessel compartment and permeability parameters using hotspot and histogram analysis.
Santarosa C; Castellano A; Conte GM; Cadioli M; Iadanza A; Terreni MR; Franzin A; Bello L; Caulo M; Falini A; Anzalone N
Eur J Radiol; 2016 Jun; 85(6):1147-56. PubMed ID: 27161065
[TBL] [Abstract][Full Text] [Related]
8. Dynamic susceptibility contrast and dynamic contrast-enhanced MRI characteristics to distinguish microcystic meningiomas from traditional Grade I meningiomas and high-grade gliomas.
Hussain NS; Moisi MD; Keogh B; McCullough BJ; Rostad S; Newell D; Gwinn R; Foltz G; Mayberg M; Aguedan B; Good V; Fouke SJ
J Neurosurg; 2017 Apr; 126(4):1220-1226. PubMed ID: 27285539
[TBL] [Abstract][Full Text] [Related]
9. Quantitative dynamic susceptibility contrast perfusion-weighted imaging-guided customized gamma knife re-irradiation of recurrent high-grade gliomas.
Wang B; Zhao P; Zhang Y; Ge M; Lan C; Li C; Pang Q; Xu S; Liu Y
J Neurooncol; 2018 Aug; 139(1):185-193. PubMed ID: 29696532
[TBL] [Abstract][Full Text] [Related]
10. Impact of
Debus C; Waltenberger M; Floca R; Afshar-Oromieh A; Bougatf N; Adeberg S; Heiland S; Bendszus M; Wick W; Rieken S; Haberkorn U; Debus J; Knoll M; Abdollahi A
Sci Rep; 2018 May; 8(1):7201. PubMed ID: 29740097
[TBL] [Abstract][Full Text] [Related]
11. Arterial Spin-Labeling and DSC Perfusion Metrics Improve Agreement in Neuroradiologists' Clinical Interpretations of Posttreatment High-Grade Glioma Surveillance MR Imaging-An Institutional Experience.
Yamin G; Tranvinh E; Lanzman BA; Tong E; Hashmi SS; Patel CB; Iv M
AJNR Am J Neuroradiol; 2024 Apr; 45(4):453-460. PubMed ID: 38453410
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of preoperative dynamic contrast-enhanced MRI perfusion parameters for high-grade glioma patients.
Ulyte A; Katsaros VK; Liouta E; Stranjalis G; Boskos C; Papanikolaou N; Usinskiene J; Bisdas S
Neuroradiology; 2016 Dec; 58(12):1197-1208. PubMed ID: 27796446
[TBL] [Abstract][Full Text] [Related]
13. Relative value of magnetic resonance spectroscopy, magnetic resonance perfusion, and 2-(18F) fluoro-2-deoxy-D-glucose positron emission tomography for detection of recurrence or grade increase in gliomas.
Prat R; Galeano I; Lucas A; Martínez JC; Martín M; Amador R; Reynés G
J Clin Neurosci; 2010 Jan; 17(1):50-3. PubMed ID: 19959364
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Value of O-(2-[18F]-Fluoroethyl)-L-Tyrosine-Positron Emission Tomography Imaging for Histopathologic Characteristics and Progression-Free Survival in Patients with Low-Grade Glioma.
Bette S; Gempt J; Delbridge C; Kirschke JS; Schlegel J; Foerster S; Huber T; Pyka T; Zimmer C; Meyer B; Ringel F
World Neurosurg; 2016 May; 89():230-9. PubMed ID: 26855307
[TBL] [Abstract][Full Text] [Related]
15. Perfusion MRI as the predictive/prognostic and pharmacodynamic biomarkers in recurrent malignant glioma treated with bevacizumab: a systematic review and a time-to-event meta-analysis.
Choi SH; Jung SC; Kim KW; Lee JY; Choi Y; Park SH; Kim HS
J Neurooncol; 2016 Jun; 128(2):185-94. PubMed ID: 27108275
[TBL] [Abstract][Full Text] [Related]
16. Differentiation of primary central nervous system lymphoma and high-grade glioma with dynamic susceptibility contrast-enhanced perfusion magnetic resonance imaging.
Liao W; Liu Y; Wang X; Jiang X; Tang B; Fang J; Chen C; Hu Z
Acta Radiol; 2009 Mar; 50(2):217-25. PubMed ID: 19096950
[TBL] [Abstract][Full Text] [Related]
17. Comparison of 18F-FET PET and perfusion-weighted MR imaging: a PET/MR imaging hybrid study in patients with brain tumors.
Filss CP; Galldiks N; Stoffels G; Sabel M; Wittsack HJ; Turowski B; Antoch G; Zhang K; Fink GR; Coenen HH; Shah NJ; Herzog H; Langen KJ
J Nucl Med; 2014 Apr; 55(4):540-5. PubMed ID: 24578243
[TBL] [Abstract][Full Text] [Related]
18. Posttreatment DSC-MRI is Predictive of Early Treatment Failure in Children with Supratentorial High-Grade Glioma Treated with Erlotinib.
Lucas JT; Knapp BJ; Uh J; Hua CH; Merchant TE; Hwang SN; Patay Z; Broniscer A
Clin Neuroradiol; 2018 Sep; 28(3):393-400. PubMed ID: 28382379
[TBL] [Abstract][Full Text] [Related]
19. Survival prediction in high-grade gliomas using CT perfusion imaging.
Yeung TP; Wang Y; He W; Urbini B; Gafà R; Ulazzi L; Yartsev S; Bauman G; Lee TY; Fainardi E;
J Neurooncol; 2015 May; 123(1):93-102. PubMed ID: 25862005
[TBL] [Abstract][Full Text] [Related]
20.
Fleischmann DF; Unterrainer M; Bartenstein P; Belka C; Albert NL; Niyazi M
J Neurooncol; 2017 Apr; 132(2):277-286. PubMed ID: 28102485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
